OTHER HIGHLIGHTS. A 12.5% increase in shift and weekend premium (from $2.00 to $2.25 an hour). Our shift and weekend premiums are now the highest in the federal law enforcement community, and greatly exceed other major law enforcement organizations such as the OPP and Sûreté du Québec. - Employees will now be able to access 4 weeks of vacation leave at 7 years of employment instead of 8 years of employment. - Employees in Intelligence, Investigations and Inland Enforcement to now be reimbursed for up to $500.00 a year for the purchase of plain clothes. - A new annual Hearings officer allowance of $500.00. - A new pensionable, annual $1000.00 allowance for non-uniform employees. - Improvements regarding travelling time, including a reduction from 40 nights to 20 nights to access an additional day of leave. - Expanded access to Family-Related Responsibility and Bereavement Leave. - Employees entitled to additional money should the employer delay implementation of the contract. - Employer must now reimburse employees for cost of medical certificates (up to $35.00).
OTHER HIGHLIGHTS. A 12.5% increase in shift and weekend premium (from $2.00 to $2.25 an hour). Our shift and weekend premiums are now the highest in the federal law enforcement community, and greatly exceed other major law enforcement organizations such as the OPP. - Employees will now be able to access 4 weeks of vacation leave at 7 years of employment instead of 8 years of employment. - Employees in Intelligence, Investigations and Inland Enforcement to now be reimbursed for up to $500.00 a year for the purchase of plain clothes. - A new annual Hearings officer allowance of $500.00. - A new pensionable, annual $1000.00 allowance for non-uniform employees. - Improvements regarding travelling time, including a reduction from 40 nights to 20 nights to access an additional day of leave. - Expanded access to Family-Related Responsibility and Bereavement Leave. - Employees entitled to additional money should the employer delay implementation of the contract. - Employer must now reimburse employees for cost of medical certificates (up to $35.00).
OTHER HIGHLIGHTS. The other major improvements to the Collective Agreement are: Stronger contracting out language that provides protection for all regular employees in the bargaining until (versus current language that protects only employees on staff on the date of ratification).
OTHER HIGHLIGHTS. XXXXXXXXX remains unchanged and all eligible members will be able to continue to accumulate severance. The Joint Labour Management Committee Article has been strengthened and a trial Joint Learning Program has been agreed to whereby the Union and the Employer will co-develop and co-deliver training programs. The training topics will be co-selected and developed and could include for example, mental health in the workplace and joint committees
OTHER HIGHLIGHTS. ⮚ Memorandum of Understanding concerning ongoing discussions about access to a benefit plan. ⮚ Improvements to the posting process. ⮚ Employer to provide ergonomic chair in each classroom. The ratification kit provides a list of all changes made to the Collective Agreement. The voting process shall be a ratification vote. All members will have the option to ratify or reject the tentative agreement. Once the members have ratified the tentative agreement, your bargaining team will sign a new Collective Agreement with Saint Xxxx University. Your bargaining team: Xxxxxxx Xxxxxx, Local President Xxxxx Xxxxxxxx, Bargaining Team Member Xxxxxx Xxxxxx, Bargaining Team Member Xxxxxx-Xxxxxx Xxxxxx, PSAC Negotiator Xxxxxx Xxxxxxx, PSAC Research Officer unanimously endorses this tentative agreement. In Solidarity, <.. image(A signature on a white background Description automatically generated) removed ..>
OTHER HIGHLIGHTS. SFX‐01 is a patented composition of synthetic sulforaphane and alpha‐cyclodextrin and is the only grade of sulforaphane suitable for clinical research and eventual approval as a medicine. Previous studies with other sources of sulforaphane have shown evidence of clinical efficacy in improving symptoms of ASD (x.x. Xxxxx et al 2014). However, patient heterogeneity provides a challenge in identifying those individuals most likely to respond to therapy. • Stalicla has a unique, proprietary technology to identify ASD patients who are most likely to respond to SFX‐01. This screening approach has already been used successfully to identify ideal patients for other ASD drug trials and is a key differentiator for Stalicla in developing drugs for such a wide spectrum disorder as ASD. • Evgen's partnership with Stalicla will enable the targeting of patient groups most likely to benefit from SFX‐01, not only de‐risking the clinical development but potentially bringing a therapeutic option to those individuals who are currently underserved, in a quick and efficient manner. • Evgen and Stalicla will collaborate initially on a clinical programme in ASD, with Stalicla funding all clinical development activities. This licensing deal is further validation of Xxxxx's stated strategy of early partnering of indications with high quality partners who can add significant value to its programmes. This follows the 2020 deal with JuvLife for use of the Sulforadex® technology in nutraceutical markets.
